Advances in heart and lung transplantation 2004: Report from the 24th International Society for Heart and Lung Transplantation Annual Meeting, San Francisco, April 21-24, 2004

Journal of Heart and Lung Transplantation

Volumn 23, Issue 8, 2004, Pages 925-930

  Mehra, Mandeep R ^a   Kobashigawa, Jon A ^b  

^a OCHSNER CLINIC FOUNDATION   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CYCLOSPORIN DERIVATIVE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; STEROID; TACROLIMUS;

CLINICAL TRIAL; CONFERENCE PAPER; DRUG DOSE REGIMEN; GRAFT REJECTION; HEALTH PROGRAM; HEART GRAFT; HEART LUNG TRANSPLANTATION; HEART MUSCLE BIOPSY; HEMODYNAMIC MONITORING; HLA MATCHING; HUMAN; LITERATURE; MEDICAL SOCIETY; PRIORITY JOURNAL; PUBLICATION; STATISTICAL SIGNIFICANCE; SURVIVAL RATE;

GRAFT SURVIVAL; HEART-LUNG TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERNATIONALITY; SURVIVAL ANALYSIS; TACROLIMUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 4243153847     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2004.05.002     Document Type: Conference Paper

References (32)

1. M.E. Billingham, N.R. Cary, M.E. Hammond A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group. The International Society for Heart Transplantation J Heart Transplant 9 1990 587 593
2. H. Valantine Cardiac allograft vasculopathy after heart transplantation risk factors and management J Heart Lung Transplant 23 suppl 5 2004 S187 S193
3. J.A. Kobashigawa First-year intravascular ultrasound results as a surrogate marker for outcomes after heart transplantation J Heart Lung Transplant 22 2003 711 714
4. M.R. Mehra, P.A. Uber TOR inhibitors and cardiac allograft vasculopathy is inhibition of intimal thickening an adequate surrogate of benefit? J Heart Lung Transplant 22 2003 501 504
5. P.R. Rickenbacher, F.J. Pinto, N.P Lewis Prognostic importance of intimal thickness as measured by intracoronary ultrasound after cardiac transplantation Circulation 92 1995 3445 3452
6. M.R. Mehra, H.O. Ventura, R. Chambers Predictive model to assess risk for cardiac allograft vasculopathy an intravascular ultrasound study JAMA 26 1995 1537 1544
7. S.R. Kapadia, K.M. Ziada, P.L. LAllier Intravascular ultrasound imaging after cardiac transplantation advantage of multi-vessel imaging J Heart Lung Transplant 19 2000 167 172
8. H.O. Ventura, M.R. Mehra C-reactive protein and cardiac allograft vasculopathy. Is inflammation the critical link JAMA 42 2003 483 485
9. H.J. Eisen, E.M. Tuzcu, R. Dorent Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients N Engl J Med 349 2003 847 858
10. E.M. Tuzcu, J.A. Kobashigawa, H.J. Eisen Favorable effect of Everolimus on cardiac allograft vasculopathy is maintained through 24 months J Heart Lung Transplant 23 suppl 2004 S51
11. A. Keogh, D. Muller, S. Faddy, P. Ruygrok, M. Richardson, A. Galbraith Sirolimus from the time of heart transplantationpersistent protection from graft vasculopathy at 2 years J Heart Lung Transplant 23 suppl 2004 S106 S107
12. J.A. Kobashigawa, J. Tobis, R.M. Mentzer Further analysis of the intravascular ultrasound data from the randomized mycophenolate mofetil (MMF) trial in heart transplant recipients J Heart Lung Transplant 23 suppl 2004 S42
13. J.A. Kobashigawa, L. Miller, D. Renlund A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators Transplantation 66 1998 507 515
14. J.D. Hosenpud, L.E. Bennett Mycophenolate mofetil versus azathioprine in patients surviving the initial cardiac transplant hospitalization an analysis of the Joint UNOS/ISHLT Thoracic Registry Transplantation 72 2001 1662 1665
15. M.R. Mehra, P.A. Uber, A.K. Prasad Long-term outcome of cardiac allograft vasculopathy treated by transmyocardial laser revascularization early rewards, late losses J Heart Lung Transplant 19 2000 801 804
16. J. Segovia, L. Alonso-Pulpn, P. Ortiz Rapastat: evaluation of the role of oral sirolimus in the treatment of established graft vessel disease. a prospective, randomized intravascular ultrasound study J Heart Lung Transplant 23 suppl 2004 S51 S52
17. D. Mancini, S. Pinney, D. Burkhoff Use of rapamycin slows progression of cardiac transplantation vasculopathy Circulation 108 2003 48 53
18. Mehra MR, Benza R, Deng MC, Russel S, Webber S. Surrogate markers for late cardiac allograft survival. Am J Transplant (in press).
19. D.O. Taylor, M.L. Barr, B. Radovancevic A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation decreased hyperlipidemia and hypertension with tacrolimus J Heart Lung Transplant 18 1999 336 345
20. M.R. Mehra, P.A. Uber, R.L. Scott, M.H. Park Ethnic disparity in clinical outcome after heart transplantation is abrogated using tacrolimus and mycophenolate mofetil-based immunosuppression Transplantation 74 2002 1568 1573
21. J.A. Kobashigawa, L. Miller, S. Russell A randomized, prospective, multi-center comparison of tacrolimus, mycophenolate mofetil (MMF) and steroids vs. cyclosporine (modified USP), MMF and steroids vs tacrolimus, sirolimus and steroids in de novo cardiac transplant recipients6 month report J Heart Lung Transplant 23 suppl 2004 S106
22. M.C. Deng, M.R. Mehra, H.J. Eisen Cardiac allograft monitoring using a novel clinical algorithm based on peripheral leukocyte gene expression profiling Circulation 108 suppl 2003 1801IV-388
23. M.R. Mehra, J. Kobashigawa, S. Hunt Molecular testing and prediction of clinical outcome in heart transplantation a prospective multicenter trial J Heart Lung Transplant 23 suppl 2004 S106
24. G.J. Burkart, G.C. Smaldone, M.A. Eldon Lung deposition and pharmacokinetics of cyclosporine after aerosolization in lung transplant patients Pharm Res 20 2003 252 256
25. A.T. Iacono, B.A. Johnson, T.E. Corcoran A randomized trial of early administration of inhaled cyclosporine in lung transplant recipients J Heart Lung Transplant 23 suppl 2004 S175
26. T.G. Liou, B.C. Cahill, F.R. Adler, B.C. Marshall Selection of patients with cystic fibrosis for lung transplantation Curr Opin Pulm Med 86 2002 535 541
27. O. Sitbon, M. Humbert, H. Nunes Long-term intravenous epoprostenol infusion in primary pulmonary hypertension prognostic factors and survival JAMA 40 2002 780 788
28. M.H. Park, R.L. Scott, P.A. Uber, M.L. Franklin, H.O. Ventura, M.R. Mehra Alteration in b-type natriuretic peptide levels with epoprostenol therapy in pulmonary hypertension an important marker of clinical outcome J Heart Lung Transplant 23 suppl 2004 S55
29. P.J. Hauptman Clinton redux its the malignancy, stupid! J Heart Lung Transplant 23 suppl 2004 S120 S121
30. A.R. Glanville The Lazarus syndrome and the cult of the super-hero J Heart Lung Transplant 23 suppl 2004 S121
31. O.E. Pajaro Transplant rejection vertebrate animals programmed maintenance of internal dynamic molecular architecture J Heart Lung Transplant 23 suppl 2004 S121 S122
32. R.L. Kormos Why left ventricular assist devices are not yet a product that has matured to the tornado phase of the market or why arent we using more LVADs? J Heart Lung Transplant 23 suppl 2004 S122